Search

Skip to main content Grants Dates Principal Investigator(s) Grant No./ Donor Title Goal 09/2025 – 08/2028 Li Liu, PhD 25-30-73-LIU, AACR Imaging-Guided Assessment of Synergistic Treatments for Breast Cancer Develop combination therapies with Cyclopamine Tartrate (CycT) that can normalize the tumor mi…

Skip to main content Publications Laterality and Sex Differences of Human Lateral Habenula Afferent and Efferent Fiber Tracts. Hitti FL, Parker D, Yang AI, Brem S, Verma R, 2022 Front Neurosci 16 837624 Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression:…

The Bartelt Lab is focused on understanding the epigenetic basis of cerebellar neurodegenerative disorders to develop holistic gene therapies. Using single-cell and spatial sequencing approaches, we profile healthy and diseased states to identify gene regulatory mechanisms in disease and utilize functional genomic tools to advance therapeutic approaches. 

The Bowen Lab focuses on the development of hybrid positron emission tomography (PET) (e.g. PET-CT and PET-MR) tools to enable precision imaging for the care and study of oncology, neurology, and cardiology patients.

Our group initially investigated a novel immune checkpoint inhibitor targeting a rare heparan sulfate (rHS) in melanoma treatment. Collaboratively, we explored the potential of a single-domain humanized rHS antibody (1A7 clone) that inhibits DC-HIL function and also angiogenesis and chemokine effects linked to diverse cancer progression signaling pathways. This experience provided insights into rHS-targeting as a promising approach to melanoma therapy.

The Neuro-Oncology Translational Research Laboratory studies primary brain tumors from pure basic science through the continuum to clinical trials. 

The Bailey lab focuses on developing gene therapies for neurological disorders. We work on monogenetic pediatric disorders, including SLC13A5 epileptic encephalopathy, multiple sulfatase deficiency, Charcot Marie Tooth disease type 4J, giant axonal neuropathy and ECHS1 deficiency.

Our laboratory is interested in improving treatment for patients with glioblastoma (GBM) and other cancers. We work on understanding signal transduction pathways involved in the pathogenesis of cancer. Recent work has focused on investigating mechanisms of resistance to targeted treatment in GBM and lung cancer. We are also interested in mechanisms regulating invasion in GBM. 

The Chong Research group has been conducting clinical and translational research on cutaneous lupus including outcome measure development for clinical trials, biomarkers for diagnosis and prognosis, and disease outcomes.

The Busch Lab develops optical technologies for minimally and non-invasive bedside assessment of microvascular blood flow and oxygen saturation, allowing continuous assessment of aerobic metabolism.